Evidence map›Paper›PMID 39036871›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial.

Brooke A Jarrett, Kate Shearer, Katlego Motlhaoleng, Sandy Chon, Gaolaolwe Gabriel Letuba, Cokiswa Qomfo, Lawrence H Moulton, Silvia Cohn, Limakatso Lebina, Richard E Chaisson and 3 more

Registry-linked trialAbstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02119130 (Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in South Africa), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02119130 nacompletednot on this map

Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in South Africa

TypeinterventionalSponsorJohns Hopkins UniversityRan2014 to 2019Enrolled3,506ConditionsLatent Tuberculosis, HIVArmsQGIT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Brooke A JarrettDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-2966-3521
Kate ShearerCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Katlego MotlhaolengPerinatal HIV Research Unit, The University of the Witwatersrand, Soweto, South Africa.
Sandy ChonCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Gaolaolwe Gabriel LetubaPerinatal HIV Research Unit, The University of the Witwatersrand, Soweto, South Africa.
Cokiswa QomfoPerinatal HIV Research Unit, The University of the Witwatersrand, Soweto, South Africa.
Lawrence H MoultonCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Silvia CohnCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Limakatso LebinaPerinatal HIV Research Unit, The University of the Witwatersrand, Soweto, South Africa.
Richard E ChaissonCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Ebrahim VariavaDepartment of Internal Medicine, Klerksdorp-Tshepong Hospital Complex, Klerksdorp, South Africa.
Neil A MartinsonCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Jonathan E GolubDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.

Funding

Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in BrazilR01AI095041 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GOLUB, JONATHAN E. · 2013 to 2017
$3.4M
The Role of an Artificially Intelligent Chatbot in Social Support, Antiretroviral Adherence, and Depressive Symptoms among Young Adults Living with HIV in South AfricaF31MH121128 · NIMH · JOHNS HOPKINS UNIVERSITY · PI JARRETT, BROOKE · 2020 to 2021
$92k
National Institute of Allergy and Infectious Diseases R01AI095041NIAID NIH HHS R01 AI095041NIHNIMH NIH HHS F31 MH121128NIMH NIH HHS F31MH121128U.S. National Institute of Allergy and Infectious Diseases R01AI095041U.S. National Institute of Mental Health F31MH121128
6 · The paper itself

Abstract

backgroundTuberculosis (TB) preventive therapy (TPT) reduces the risk of TB disease in people with human immunodeficiency virus (HIV), yet uptake has been suboptimal in many countries. We assessed whether QuantiFERON Gold In-Tube (QGIT) during routine HIV care increased TB infection (TBI) testing and TPT prescriptions.

methodsThis parallel-arm, 1:1 cluster-randomized controlled trial compared the standard-of-care tuberculin skin test to QGIT in South Africa. We enrolled consenting, TPT-eligible adults diagnosed with HIV ≤30 days prior and used intention-to-treat analyses for the outcomes: proportion of patients with documented TBI results, proportion with documented TPT, and time from enrollment to outcomes.

findingsWe enrolled 2232 patients across 14 clinics from November 2014 to May 2017 (58% in intervention clinics). At 24 months of follow-up, more participants in intervention clinics had TBI results (69% vs 2%, P < .001) and TPT prescriptions (45% vs 30%, P = .13) than control clinics. Controlling for baseline covariates, intervention clinics had 60% (95% confidence interval, 51-68; P < .001) more participants with TBI results and 12% (95% confidence interval, -6 to 31; P = .18) more with TPT prescriptions. Among participants with results, those in intervention clinics received results and TPT faster (intervention: median of 6 and 29 days after enrollment vs control: 21 and 54 days, respectively).

interpretationIn this setting, QGIT in routine HIV care resulted in more patients with TBI results. Clinicians also initiated more people with HIV on TPT in QGIT intervention clinics, and did so more quickly, than the control arm. CLINICAL TRIALS REGISTRATION: NCT02119130.

Indexed as

HIV InfectionsTuberculin TestTuberculosisAdultAntitubercular AgentsFemaleHumansInterferon-gamma Release TestsMaleMiddle AgedSouth AfricaAntitubercular AgentsHIVinterferon-gamma release testslatent tuberculosisprevention and controltuberculin test

Identifiers

PMID39036871
PMCPMC11426260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.